Montserrat Jaumot

Montserrat Jaumot

Auto-generated profile, based on publicly available information

Montserrat Jaumot

Laboratory of Experimental Oncology, Department of Pathology, University of Queensland Medical School, Herston Road, Queensland 4006, Australia

Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

1 September 1997 in Plant and Soil
Verified
Journal Article
Closed access
PDF file
MJM.C. Jaizme-Vega
M.C. Jaizme-Vega
PTP. Tenoury
P. Tenoury
JPJ. Pinochet
J. Pinochet
MJM. Jaumot
M. Jaumot

1 November 1999 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
JEJosep Maria Estanyol
Josep Maria Estanyol
MJMontserrat Jaumot
Montserrat Jaumot
OCOriol Casanovas
Oriol Casanovas
ARAina Rodriguez-Vilarrupla
Aina Rodriguez-Vilarrupla
NANeus Agell
Neus Agell
OBOriol Bachs
Oriol Bachs
The cyclin-dependent kinase (CDK) inhibitor p21Cip1 has a dual role in the regulation of the cell cycle; it is an activator of cyclin D1-CDK4 complexes and an inhibitor of cyclins E/A-CDK2 activity. By affinity chromatography with p21Cip1-Sepharose 4B columns, we purified a 39-kDa protein, which was identified by microsequence analysis as the oncoprotein SET. Complexes containing SET and p21Cip1 were detected in vivo by immunoprecipitation of Namalwa cell extracts using specific anti-p21Cip1 antibodies. We found that SET bound directly to p21Cip1 in vitro by the carboxyl-terminal region of p21Cip1. SET had no direct effect on cyclin E/A-CDK2 activity, although it reversed the inhibition of cyclin E-CDK2, but not of cyclin A-CDK2, induced by p21Cip1. This result is specific for p21Cip1, since SET neither bound to p27Kip1 nor reversed its inhibitory effect on cyclin E-CDK2 or cyclin A-CDK2. Thus, SET appears to be a modulator of p21Cip1 inhibitory function. These results suggest that SET can regulate G1/S transition by modulating the activity of cyclin E-CDK2.

1 January 2002 in Journal of Biological Chemistry
Verified
Journal Article
Open access
MJMontserrat Jaumot
Montserrat Jaumot
JYJun Yan
Jun Yan
JCJodi Clyde-Smith
Jodi Clyde-Smith
JSJudith Sluimer
Judith Sluimer
JHJohn F Hancock
John F Hancock
Ha-Ras and Ki-Ras have different distributions across plasma membrane microdomains. The Ras C-terminal anchors are primarily responsible for membrane micro-localization, but recent work has shown that the interaction of Ha-Ras with lipid rafts is modulated by GTP loading via a mechanism that requires the hypervariable region (HVR). We have now identified two regions in the HVR linker domain that regulate Ha-Ras raft association. Release of activated Ha-Ras from lipid rafts is blocked by deleting amino acids 173-179 or 166-172. Alanine replacement of amino acids 173-179 but not 166-172 restores wild type micro-localization, indicating that specific N-terminal sequences of the linker domain operate in concert with a more C-terminal spacer domain to regulate Ha-Ras raft association. Mutations in the linker domain that confine activated Ha-RasG12V to lipid rafts abrogate Raf-1, phosphoinositide 3-kinase, and Akt activation and inhibit PC12 cell differentiation. N-Myristoylation also prevents the release of activated Ha-Ras from lipid rafts and inhibits Raf-1 activation. These results demonstrate that the correct modulation of Ha-Ras lateral segregation is critical for downstream signaling. Mutations in the linker domain also suppress the dominant negative phenotype of Ha-RasS17N, indicating that HVR sequences are essential for efficient interaction of Ha-Ras with exchange factors in intact cells.

1 October 2014 in Gastroenterology
Verified
Journal Article
Open access
CBCarles Barceló
Carles Barceló
JEJulia Etchin
Julia Etchin
MMMarc R. Mansour
Marc R. Mansour
TSTakaomi Sanda
Takaomi Sanda
MGMireia Morell Ginestà
Mireia Morell Ginestà
NANeus Agell
Neus Agell
Development of pancreatic ductal adenocarcinoma (PDAC) involves activation of c-Ki-ras2 Kirsten rat sarcoma oncogene homolog (KRAS) signaling, but little is known about the roles of proteins that regulate the activity of oncogenic KRAS. We investigated the activities of proteins that interact with KRAS in PDAC cells. We used mass spectrometry to demonstrate that heterogeneous nuclear ribonucleoproteins (HNRNP) A2 and B1 (encoded by the gene HNRNPA2B1) interact with KRAS G12V. We used co-immunoprecipitation analyses to study interactions between HNRNPA2B1 and KRAS in KRAS-dependent and KRAS-independent PDAC cell lines. We knocked down HNRNPA2B1 using small hairpin RNAs and measured viability, anchorage-independent proliferation, and growth of xenograft tumors in mice. We studied KRAS phosphorylation using the Phos-tag system. We found that interactions between HRNPA2B1 and KRAS correlated with KRAS-dependency of some human PDAC cell lines. Knock down of HNRNPA2B1 significantly reduced viability, anchorage-independent proliferation, and formation of xenograft tumors by KRAS-dependent PDAC cells. HNRNPA2B1 knock down also increased apoptosis of KRAS-dependent PDAC cells, inactivated c-akt murine thymoma oncogene homolog 1 signaling via mammalian target of rapamycin, and reduced interaction between KRAS and phosphatidylinositide 3-kinase. Interaction between HNRNPA2B1 and KRAS required KRAS phosphorylation at serine 181. In KRAS-dependent PDAC cell lines, HNRNPA2B1 interacts with and regulates the activity of KRAS G12V and G12D. HNRNPA2B1 is required for KRAS activation of c-akt murine thymoma oncogene homolog 1-mammalian target of rapamycin signaling, interaction with phosphatidylinositide 3-kinase, and PDAC cell survival and tumor formation in mice. HNRNPA2B1 might be a target for treatment of pancreatic cancer.

15 February 2014 in Cancer Research
Verified
Journal Article
Open access
PDF file
CBCARLES BARCELÓ
CARLES BARCELÓ
NPNoelia Paco
Noelia Paco
MGMireia Morell Ginestà
Mireia Morell Ginestà
BABlanca Alvarez-Moya
Blanca Alvarez-Moya
NBNeus Bota-Rabassedas
Neus Bota-Rabassedas
NANeus Agell
Neus Agell
KRAS phosphorylation has been reported recently to modulate the activity of mutant KRAS protein in vitro. In this study, we defined S181 as a specific phosphorylation site required to license the oncogenic function of mutant KRAS in vivo. The phosphomutant S181A failed to induce tumors in mice, whereas the phosphomimetic mutant S181D exhibited an enhanced tumor formation capacity, compared with the wild-type KRAS protein. Reduced growth of tumors composed of cells expressing the nonphosphorylatable KRAS S181A mutant was correlated with increased apoptosis. Conversely, increased growth of tumors composed of cells expressing the phosphomimetic KRAS S181D mutant was correlated with increased activation of AKT and ERK, two major downstream effectors of KRAS. Pharmacologic treatment with PKC inhibitors impaired tumor growth associated with reduced levels of phosphorylated KRAS and reduced effector activation. In a panel of human tumor cell lines expressing various KRAS isoforms, we showed that KRAS phosphorylation was essential for survival and tumorigenic activity. Furthermore, we identified phosphorylated KRAS in a panel of primary human pancreatic tumors. Taken together, our findings establish that KRAS requires S181 phosphorylation to manifest its oncogenic properties, implying that its inhibition represents a relevant target to attack KRAS-driven tumors. Cancer Res; 74(4); 1190–9. ©2013 AACR.